(PRNewsfoto/Sun Pharmaceutical Industries Inc., USA (Sun Pharma)) Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers.

“We are positive on these three stocks—Sun Pharma, Dr Reddy’s, and Lupin—despite the tariff announcements. India remains the ‘pharmacy of the world,’ and there’s no challenge to its ...

Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma's specialty portfolio ...

The acquisition will bolster Sun Pharma’s onco-dermatology portfolio, adding Checkpoint’s recently FDA-approved cancer drug, UNLOXCYT (cosibelimab-ipdl), to its pipeline. The deal, expected to ...

A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai, India, November 14, 2017.(Shailesh Andrade/Reuters) This is also Sun Pharma's second acquisition ...

Sun Pharma is set to acquire Checkpoint Therapeutics for $355 million, enhancing its specialty portfolio with UNLOXCYT, an FDA-approved treatment for advanced skin cancer. This acquisition aims to ...

The share price of Sun Pharmaceuticals Industries (Sun Pharma) is shining bright, the top gainer in intra-day trade, up 3%. This surge in the share price came after the company announced an ...

Inc. have announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company. Checkpoint is a commercial-stage company ...

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations. Last year, it signed ...

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma. Sun Pharma announced ...

Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of $355 million, or $4.10 per share, the companies said Sunday. With Unloxcyt, an FDA-approved PD-L1 therapy for ...